Screener
Syndax Pharmaceuticals SNDX Business Segments — Cost Of Product Sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept sndx:CostOfProductSales.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Collaboration revenue, net | 15,941 | — |
| Total revenues | 64,864 | 20,042 |
| Operating expenses: | ||
| Cost of product sales | $2,633 | $885 |
| Research and development | 58,845 | 61,636 |
| Selling, general and administrative | 37,588 | 41,031 |
| Collaboration loss | — | 247 |
| Total operating expenses | 99,066 | 103,799 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's business segments — cost of product sales?
- Syndax Pharmaceuticals (SNDX) reported business segments — cost of product sales of $2.63M in Q1 2026.
- How has Syndax Pharmaceuticals's business segments — cost of product sales changed year-over-year?
- Syndax Pharmaceuticals's business segments — cost of product sales increased by 197.5% year-over-year, from $885K to $2.63M.
- What does business segments — cost of product sales mean?
- This represents the direct costs incurred to manufacture and distribute pharmaceutical products sold within the cancer therapeutics segment. It includes raw materials, labor, and overhead directly attributable to the production process. Monitoring this metric helps assess the gross margin efficiency and the scalability of the company's manufacturing operations.
Ask your AI about Syndax Pharmaceuticals's business segments — cost of product sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude